Abstract: The present invention relates to a method of modifying at least one gene in a cell via CRISPR/Cas, wherein the at least one gene has at least three alleles. The present invention further relates to cells obtainable by the method of the invention. Additionally, the present invention provides a method of producing a protein in a cell obtainable by the method of modifying at least one gene of the invention. Moreover, the invention relates to proteins obtainable by the method of producing a protein and use thereof, for example in therapy.

Abstract: The present invention relates to a method of modifying at least one gene in a cell via CRISPR/Cas, wherein the at least one gene has at least three alleles. The present invention further relates to cells obtainable by the method of the invention. Additionally, the present invention provides a method of producing a protein in a cell obtainable by the method of modifying at least one gene of the invention. Moreover, the invention relates to proteins obtainable by the method of producing a protein and use thereof, for example in therapy.

Abstract: The present invention relates to a method of modifying at least one gene in a cell via CRISPR/Cas, wherein the at least one gene has at least three alleles. The present invention further relates to cells obtainable by the method of the invention. Additionally, the present invention provides a method of producing a protein in a cell obtainable by the method of modifying at least one gene of the invention. Moreover, the invention relates to proteins obtainable by the method of producing a protein and use thereof, for example in therapy.

Abstract: The present invention pertains to fusion protein constructs comprising an antibody against the cancer antigen MUC1 and IL-15. In particular, the fusion protein constructs activate NK cells and T cells at the cancer site.

Abstract: The present invention relates to an antibody which effects enhanced T cell activation in comparison to a reference antibody being glycosylated including more than 80% core-fucosylation and wherein T cell activation is effected by an antibody characterized by enhanced binding to Fc#RIIIa. Said antibody is glycosylated, but essentially lacks core-fucosylation.

Abstract: The present invention pertains to multispecific antibody constructs directed against the cancer antigen MUC1 and the T cells antigen CD3. In particular, the multispecific antibody constructs recruit T cells to the cancer site. The design of the multispecific antibody constructs show strong antigen binding and high T cell activation.

Abstract: The present invention pertains to humanized anti-CD40 antibodies having antigen binding properties similar to those of the parent chimeric anti-CD40 antibody and increased Fc? receptor binding affinities. In particular, the present invention is directed to humanized anti-CD40 antibodies which are useful in the treatment of cancer, infections and immunodeficiencies.

Abstract: The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.

Abstract: The present invention pertains to the field of cancer therapy using anti-cancer antibodies. The medical use of anti-MUC1 antibodies in combination with inhibitors of the ErbB receptor family is provided which show synergistic anti-cancer efficacy.

Abstract: The present invention relates to means and method for isolating naturally-occurring microorganisms (non-pathogenic bacteria, yeasts or fungi) capable of binding toxins from microorganisms such as bacteria, viruses, fungi, yeasts, or protozoans and/or receptors for these toxins on the surface of mammalian cells, thereby making these receptors inaccessible for said toxins. The naturally-occurring microorganisms that are obtainable by the means and methods of the present invention can be used for adsorbing toxins from pathogenic microorganisms and/or blocking receptors for such toxins on the surface of mammalian cells. These toxin-receptor interactions are known to be critical for disease pathogenesis, making both the toxins and receptors a target for the naturally-occurring microorganisms of the present invention.

Abstract: The present invention relates to a method of modifying at least one gene in a cell via CRISPR/Cas, wherein the at least one gene has at least three alleles. The present invention further relates to cells obtainable by the method of the invention. Additionally, the present invention provides a method of producing a protein in a cell obtainable by the method of modifying at least one gene of the invention. Moreover, the invention relates to proteins obtainable by the method of producing a protein and use thereof, for example in therapy.

Abstract: The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.

Abstract: The present invention pertains to the field of recombinant protein production. Novel expression cassettes comprising elements of the human globin gene clusters are provided which show enhanced expression rates of proteins or polypeptides of interest.

Abstract: The present invention pertains to the field of gonadotropins. In particular, an improved composition comprising recombinant human follicle-stimulating hormone and chlorocresol is provided. This improved composition has an increased stability at high temperatures and is useful in the treatment of infertility, in particular in human patients.

Abstract: This invention relates to a detection method for nucleic acids in samples that contain biological material, as well as to a kit having components with which the detection method can be carried out. In samples that contain biotechnologically produced biological material, for example, the detection method is suitable for detecting nucleic acids of host cells that were used for the production of the material.

Abstract: The present invention pertains to fusion constructs of dimeric proteins, wherein the portions of the protein are fused to either to the CH1 domain of the CL domain of an antibody. These fusion constructs improve stability, solubility, circulation half-life and production yield of the dimeric protein.

Abstract: The present invention pertains to the field of cell cultivation. Small scale cell culture systems are provided which simulate large scale perfusion cultures of suspension cells. The present invention in particular provides methods for cultivating cells wherein cell sedimentation is used to separate cells from culture medium for replacing part of the culture medium.

Abstract: The present invention pertains to the field of recombinant protein production. Novel expression cassettes comprising elements of the human globin gene clusters are provided which show enhanced expression rates of proteins or polypeptides of interest.

Abstract: The present invention relates to antibody-drug conjugates (ADCs) and a method for improving the safety profile of the same, comprising linking an antibody molecule to a drug in order to obtain said ADC, wherein said antibody molecule is obtainable from a host cell selected to produce an antibody molecule composition having specific glycosylation

Abstract: The invention relates to recognition molecules directed towards tumors, and it also relates to pharmaceutical compositions comprising said recognition molecules, methods for the production of said recognition molecules, and to the use of said recognition molecules in the diagnosis and therapy of tumor diseases.